KẾT QUẢ HÓA TRỊ UNG THƯ BIỂU MÔ BUỒNG TRỨNG TÁI PHÁT DI CĂN BẰNG PHÁC ĐỒ GEMCITABINE-CARBOPLATIN-BEVACIZUMAB

Abstract

Objectives: to evaluate outcome of gemcitabine-Carboplatin plus Bevacizumab in Platine- Sensitive-Recurrent Ovarian Cancer . Patients and Method: Descriptive, retrospective and prospective study. From January 2017 to August 2022, we enrolled 43 patients with platine sensitve - recurrent ovarian cancer at K Hospital. All patients were used chemotherapy with Gemcitabine Carboplatin plus Bevacizumab regimens. Tumor response and survival were determined. Results: Clinical features: The median of age was 57.8. The age group from 50-59 is the most common group, accounting for 41.9%. Serous adenocarcinoma was the most common histological form with 81.4%. The most common physical symptom is ascites, accounting for 55.8%, 30.2% of patients have no functional symptoms at relapse, which is detected through periodic examination. 55.8% of patients relapsed within 6-12 months after radical treatment and 44.2% relapsed after the end of initial treatment over 1 year.Results of treatment: The response rate was 72.1%, 03 patients achieved complete response accounting  for 7.0 %, partial response 65.1%. Response rates were associated with ECOG and time to relapse after completion of initial treatment. The mean progression-free survival according to Kaplan-Meier was 10.8 months, at the time of study closure there were 07 progression-free patients. Conclusion: Gemcitabine-Carboplatin- Bevacizumab regimen is effective treatment and helps prolong progression-free survival for patients with platinum-sensitive recurrent ovarian carcinoma.